[Cytolytic hepatitis and esomeprazole during chemotherapy].
BACKGROUND
Esomeprazole, the pure S isomer form of omeprazole, is indicated for the treatment of peptic esophagitis. We report here a major episode of cytolytic hepatitis following a single administration.


METHODS
A 41-year-old woman with infiltrating ductal carcinoma of the breast was undergoing chemotherapy with paclitaxel and trastuzumab. On the fourth day of the second course, she took 1 tablet of esomeprazole 20 mg for epigastric pain. Liver pain and asthenia followed, and liver function tests showed substantial cytolysis. These tests returned to normal levels despite continuation of the chemotherapy.


CONCLUSIONS
This cytolytic hepatitis is very probably imputable to esomeprazole, but a synergistic hepatic toxicity of the chemotherapy with esomeprazole cannot be ruled out.
Capitain
O
O
Centre Paul Papin, Angers.
Lortholary
A
A
Abadie-Lacourtoisie
S
S
D000328:Adult; D000897:Anti-Ulcer Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology / Q000473:pathology*; D064098:Esomeprazole / Q000009:adverse effects* / Q000627:therapeutic use*; D004941:Esophagitis / Q000139:chemically induced / Q000188:drug therapy; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage; D000068878:Trastuzumab
D000897:Anti-Ulcer Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D064098:Esomeprazole; D000068878:Trastuzumab; D017239:Paclitaxel